51S.F CYNATA THERAPEUTICS
- Market cap
- EUR 2.36M
- P/E
- -
- P/B
- 0.06x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Jun 2026.
Is 51S.F undervalued?
Graham numberThe Graham number of CYNATA THERAPEUTICS cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
CYNATA THERAPEUTICS fundamental analysis
No fundamental analysis for CYNATA THERAPEUTICS yet.
CYNATA THERAPEUTICS stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About CYNATA THERAPEUTICS
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of a proprietary induced pluripotent stem cell (iPSC)-based platform technology under the Cymerus name in Australia. The company develops CYP-004, an iPSC-derived mesenchymal stem cell (MSC) product candidate for intra-articular injection that has completed Phase 3 clinical trial for the treatment of osteoarthritis; CYP-001, an iPSC-derived MSC product candidate for …
Full company profileCYNATA THERAPEUTICS financial statements
CYNATA THERAPEUTICS annual financial statements (AUD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating Income | -13.8M | -16.5M | -12.5M | -11.5M | -9.69M |
| EBITDA | - | -16.3M | -12.3M | -11.2M | -9.43M |
| Net Income | -5.45M | -14.3M | -9.74M | -9.39M | -9.25M |
| EPS | -0.04 | -0.07 | -0.05 | -0.04 | -0.04 |
| Balance Sheet | |||||
| Total Assets | 26.5M | 19.0M | 8.39M | 7.20M | 1.35M |
| Total Liabilities | 2.59M | 2.26M | 1.17M | 1.22M | 1.91M |
| Shareholders' Equity | 24.0M | 16.7M | 7.22M | 5.98M | -554K |
| Cash & Short-term Investments | 23.8M | 16.2M | 6.21M | 5.05M | 897K |
| Cash Flow | |||||
| Capital Expenditure | 0.00 | 0.00 | 0.00 | 50.0K | 0.00 |
| Free Cash Flow | -3.30M | -14.3M | -9.96M | -8.77M | -6.74M |
| Ratios | |||||
| ROE | -22.7% | -85.3% | -135.0% | -157.0% | - |
| ROA | -20.5% | -75.2% | -116.2% | -130.5% | -682.8% |
What these items mean
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
CYNATA THERAPEUTICS dividends
CYNATA THERAPEUTICS has not paid dividends in the last 6 fiscal years.
Who owns CYNATA THERAPEUTICS
- Insiders 18.79%
- Institutions 5.37%
- Public & others 75.84%
- Shares outstanding 337M
- Free float 204M
CYNATA THERAPEUTICS company profile
- Company name
- CYNATA THERAPEUTICS
- Ticker
- 51S.F
- ISIN
- AU000000CYP7
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Fiscal year end
- June
- Address
- 100 Cubitt Street, Cremorne, VIC, Australia, 3121
- Phone
- 61 3 7067 6940
- Website
- cynata.com
About CYNATA THERAPEUTICS
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of a proprietary induced pluripotent stem cell (iPSC)-based platform technology under the Cymerus name in Australia. The company develops CYP-004, an iPSC-derived mesenchymal stem cell (MSC) product candidate for intra-articular injection that has completed Phase 3 clinical trial for the treatment of osteoarthritis; CYP-001, an iPSC-derived MSC product candidate for intravenous use that is in a Phase 1/2 clinical trial for NEREID kidney transplantation; and CYP-006TK, an iPSC-derived MSC topical wound dressing product candidate that completed a Phase 1 trial for the treatment of diabetic foot ulcer. It is also developing pre-clinical pipeline products for asthma, cancer, cardiovascular, sepsis, critical limb ischemia, and idiopathic pulmonary fibrosis indications. The company has a strategic partnership agreement with FUJIFILM Corporation, as well as partnerships with the University of Sydney and Leiden University Medical Center. The company was formerly known as Eco Quest Limited and changed its name to Cynata Therapeutics Limited in October 2013. Cynata Therapeutics Limited was incorporated in 2003 and is based in Cremorne, Australia.
CYNATA THERAPEUTICS management
1- Mr. Peter Gordon Webse B.Bus, FCIS, FCPA, FGIA, M.A.I.C.D.Company Secretary · born 1963